Federal Register / Vol. 87, No. 45 / Tuesday, March 8, 2022 / Notices 12981 

safeguards against diversion are in 

place. 

As this applicant has applied to 

become registered as a bulk 

manufacturer of marihuana, the 

application will be evaluated under the 

criteria of 21 U.S.C. 823(a). DEA will 

conduct this evaluation in the manner 

described in the rule published at 85 FR 

82333 on December 18, 2020, and 

reflected in DEA regulations at 21 CFR 

part 1318. 

In accordance with 21 CFR 

1301.33(a), DEA is providing notice that 

on September 30, 2021, Tikun Olam 

Adelanto LLC, 16605 Koala Road, 

Adelanto, California 92301–3925, 

applied to be registered as a bulk 

manufacturer of the following basic 

class(es) of controlled substances: 

Controlled substance Drug 

code Schedule 

Marihuana Extract ........ 7350 I 

Marihuana ..................... 7360 I 

Matthew J. Strait, 

Deputy Assistant Administrator. 

[FR Doc. 2022–04804 Filed 3–7–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–971] 

Importer of Controlled Substances 

Application: Caligor Coghlan Pharma 

Services 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Caligor Coghlan Pharma 

Services has applied to be registered as 

an importer of basic class(es) of 

controlled substance(s). Refer to 

SUPPLEMENTARY INFORMATION listed 

below for further drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before April 7, 2022. Such persons 

may also file a written request for a 

hearing on the application on or before 

April 7, 2022. 

ADDRESSES: The DEA requires that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. All 

requests for a hearing must be sent to: 

(1) Drug Enforcement Administration, 

Attn: Hearing Clerk/OALJ, 8701 

Morrissette Drive, Springfield, Virginia 

22152; and (2) Drug Enforcement 

Administration, Attn: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing should 

also be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on December 21, 2021, 

Caligor Coghlan Pharma Services, 1500 

Business Park Drive, Unit B, Bastrop, 

Texas 78602, applied to be registered as 

an importer of the following basic 

class(es) of controlled substance(s): 

Controlled substance Drug 

code Schedule 

Lysergic acid 

diethylamide.

7315 I 

The company plans to import drug 

Lysergic acid diethylamide (7315) in 

finished dosage forms for pediatric 

clinical trials. No other activity for this 

drug code is authorized for this 

registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

Matthew J. Strait, 

Deputy Assistant Administrator. 

[FR Doc. 2022–04807 Filed 3–7–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–970] 

Importer of Controlled Substances 

Application: Siegfried USA, LLC 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Siegfried USA, LLC has 

applied to be registered as an importer 

of basic class(es) of controlled 

substance(s). Refer to SUPPLEMENTARY

INFORMATION listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before April 7, 2022. Such persons 

may also file a written request for a 

hearing on the application on or before 

April 7, 2022. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing must 

be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for a 

hearing should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/OALJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DPW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on December 8, 2021, 

Siegfried USA, LLC, 33 Industrial Park 

Road, Pennsville, New Jersey 08070, 

applied to be registered as an importer 

of the following basic class(es) of 

controlled substance(s): 

Controlled substance Drug 

code Schedule 

Phenylacetone .............. 8501 II 

Opium, raw ................... 9600 II 

Poppy Straw Concentrate.9670 II 

The company plans to import the 

listed controlled substances to 

manufacture bulk active 

pharmaceuticals ingredients (API) for 

distribution to its customers. 

Phenylacetone will be used to 

manufacture Amphetamine. No other 


lotter on DSK11XQN23PROD with NOTICES1

I I 

I I 
12982 Federal Register / Vol. 87, No. 45 / Tuesday, March 8, 2022 / Notices 

activity for this drug code is authorized 

for this registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

Matthew J. Strait, 

Deputy Assistant Administrator. 

[FR Doc. 2022–04806 Filed 3–7–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–961] 

Importer of Controlled Substances 

Application: ANI Pharmaceuticals Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: ANI Pharmaceuticals Inc. has 

applied to be registered as an importer 

of basic class(es) of controlled 

substance(s). Refer to SUPPLEMENTARY

INFORMATION listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before April 7, 2022. Such persons 

may also file a written request for a 

hearing on the application on or before 

April 7, 2022. 

ADDRESSES: The DEA requires that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. All 

requests for a hearing must be sent to: 

(1) Drug Enforcement Administration, 

Attn: Hearing Clerk/OALJ, 8701 

Morrissette Drive, Springfield, Virginia 

22152; and (2) Drug Enforcement 

Administration, Attn: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing should 

also be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on January 6, 2022, ANI 

Pharmaceuticals Inc., 70 Lake Drive, 

East Windsor, New Jersey 08520, 

applied to be registered as an importer 

of the following basic class(es) of 

controlled substance(s): 

Controlled substance Drug 

code Schedule 

Psilocybin ..................... 7437 I 

Levorphanol .................. 9220 II 

The substance Levorphanol (9220) 

will be used to manufacture the Food 

and Drug Administration-approved 

dosage forms for distribution in the 

United States. The substance Psilocybin 

(7437) will be used to support 

formulation development and clinical 

trial research. No other activity for these 

drug codes are authorized for this 

registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food Drug Administrationapproved or non-approved finished 

dosage forms for commercial sale. 

Matthew J. Strait, 

Deputy Assistant Administrator. 

[FR Doc. 2022–04803 Filed 3–7–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

[OMB Number 1117–0006] 

Agency Information Collection 

Activities; Proposed eCollection, 

eComments Requested; Extension 

Without Change of a Previously 

Approved Collection; Application for 

Individual Manufacturing Quota for a 

Basic Class of Controlled Substance 

and for Ephedrine, Pseudoephedrine, 

and Phenylpropanolamine; DEA Form 

189 

AGENCY: Drug Enforcement 

Administration, Department of Justice. 

ACTION: 60-Day notice. 

SUMMARY: The Department of Justice, 

Drug Enforcement Administration 

(DEA), will be submitting the following 

information collection request to the 

Office of Management and Budget for 

review and approval in accordance with 

the Paperwork Reduction Act of 1995. 

This information collection is also 

associated with the proposed 

rulemaking ‘‘Management of Quotas for 

Controlled Substances and List I 

Chemicals.’’ It is likely that the final 

rule will not be published before this 

information collection expires on June 

30, 2022. If the final rule does publish 

prior to the expiration, it will be 

published as the 30-Day Notice. 

DATES: Comments are encouraged and 

will be accepted for 60 days until May 

9, 2022. 

FOR FURTHER INFORMATION CONTACT: If 

you have comments, especially on the 

estimated public burden or associated 

response time, suggestions, or need a 

copy of the proposed information 

collection instrument with instructions 

or additional information, please 

contact Scott A. Brinks, Regulatory 

Drafting and Policy Support Section 

(DPW), Diversion Control Division, Drug 

Enforcement Administration; Mailing 

Address: 8701 Morrissette Drive, 

Springfield, Virginia 22152; Telephone: 

(571) 776–2265. 

SUPPLEMENTARY INFORMATION: Written 

comments and suggestions from the 

public and affected agencies concerning 

the proposed collection of information 

are encouraged. Your comments should 

address one or more of the following 

four points: 

—Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

—Evaluate the accuracy of the agency’s 

estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

—Evaluate whether and if so how the 

quality, utility, and clarity of the 

information proposed to be collected 

can be enhanced; and 

—Minimize the burden of the collection 

of information on those who are to 

respond, including through the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms 

of information technology, e.g., 

permitting electronic submission of 

responses. 

Overview of This Information 

Collection 

1. Type of Information Collection: 

Extension of a currently approved 

collection. 


lotter on DSK11XQN23PROD with NOTICES1

I I